Reengineering the pill that fights ER+ breast cancer - and convincing Novartis to bet $250 million it will work.
Walk into 780 Brannan Street in San Francisco and you will not find the cinematic version of a cancer breakthrough. No glowing serum, no white-knuckle countdown. You will find roughly 96 people, a chemistry problem, and a single conviction that has organized the whole enterprise: that the medicines used to treat estrogen-driven breast cancer stop working too soon, and that the fix is not a flashier target but a better-built molecule.
That conviction has a name - palazestrant - and a job description that sounds modest until you sit with it. Most breast cancers are fueled by the estrogen receptor. Existing therapies turn the signal down. Olema's bet is that turning it down is not the same as turning it off, and that the difference is exactly where the cancer hides. So they built a drug to switch it off completely, and to do it in a pill a patient can take at home.
It is an unglamorous thesis. It is also why an executive who once ran global drug development at AstraZeneca walked away to run a company a fraction of the size.
Better medicines for breast cancer and beyond.Olema Oncology - the company's stated reason for existing
Olema is, in the most honest sense, a story about chemistry. Two programs do the talking.
An oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD). The distinction matters: it does not merely block the receptor, it degrades it - aiming to shut estrogen signaling all the way down. In two Phase 3 trials: OPERA-01 as monotherapy in second/third-line ER+/HER2- metastatic breast cancer, and OPERA-02 in the frontline setting paired with ribociclib.
A potent, selective KAT6 (lysine acetyltransferase 6) inhibitor now in a Phase 1 study. It is Olema's reach beyond the estrogen receptor - evidence the company wants to be read as a pipeline, not a single bet, even while palazestrant carries the headline.
The science traces back to scientific founder Peter Kushner and a long study of nuclear receptors - the cellular switches that estrogen flips. The decade of unglamorous receptor biology is the part no press release captures, and it is the part that made everything after it possible.
The operator is Sean P. Bohen, M.D., Ph.D., who became president and CEO in September 2020. Bohen had been chief medical officer and EVP of global medicines development at AstraZeneca, with senior time at Genentech before that. In an industry where leaders rarely trade scale for focus, he did the opposite - leaving one of the largest oncology operations in the world to steer a single-asset-minded biotech. The irony writes itself: one of palazestrant's rivals in the oral-SERD race is his former employer.
Focused on transforming the metastatic breast cancer treatment paradigm and improving outcomes for patients living with breast cancer and beyond.Olema Oncology - mission, as stated
Olema runs the classic clinical-stage playbook: raise patient capital, spend it on trials, repeat - with the eventual prize being an approved drug. The most telling line item is not the IPO. It is the 2024 Novartis deal, which handed Olema both a supply of the blockbuster ribociclib for its frontline trial and a $250 million equity infusion. Big pharma rarely writes that kind of check without believing the data underneath.
Preclinical data for palazestrant and OP-3136 slated for the 2026 AACR Annual Meeting.
Trial-in-progress poster for the Phase 3 OPERA-02 trial (palazestrant + ribociclib) presented at SABCS 2025.
New Phase 1b/2 data for palazestrant plus ribociclib presented at ESMO 2025.
Announced 90 mg once-daily palazestrant dose selection for pivotal Phase 3 development at ASCO 2025.
Novartis clinical collaboration and ribociclib supply agreement, alongside a $250M equity private placement.
Olema does not run a public product demo in the consumer sense - its "demo" is clinical data presented at oncology congresses (ASCO, ESMO, SABCS, AACR). The most current talks, posters, and investor updates live on the company's investor-relations channel and conference webcasts.
Investor presentations & webcasts: ir.olema.com | Pipeline & science overview: olema.com
Return to that San Francisco floor. The 96 people are still there, still working a chemistry problem that does not photograph well. But the room has changed. What started as a conviction - that you can build a better off-switch for estrogen-driven cancer - is now two Phase 3 trials, a Novartis-backed war chest, and a topline readout the entire field is waiting on for the second half of 2026.
If the data hold, the quiet lab will have done something loud: moved a homegrown pill from a hypothesis into the frontline of breast cancer care, where it could reach patients before resistance ever gets its turn. If it doesn't, the conviction will have cost a great deal to test. Either way, the wager is honest, the molecule is real, and the answer is close. That is the rarest thing in biotech - not certainty, but a clear question about to be answered.